scholarly journals Challenges of the Oral Cancer Burden in India

2012 ◽  
Vol 2012 ◽  
pp. 1-17 ◽  
Author(s):  
Ken Russell Coelho
Keyword(s):  
Oral Cancer ◽  
Disease Incidence ◽  
Cancer Control ◽  
Cancer Registries ◽  
Case Definition ◽  
World Health ◽  
Future Research ◽  
International Agency ◽  
Quality Of Data ◽  
Disease Case

Oral cancer ranks in the top three of all cancers in India, which accounts for over thirty per cent of all cancers reported in the country and oral cancer control is quickly becoming a global health priority. This paper provides a synopsis of the incidence of oral cancer in India by focusing on its measurement in cancer registries across the country. Based on the International Classification of Disease case definition adopted by the World Health Organisation, and the International Agency for Research on Cancer, this review systematically examines primary and secondary data where the incidence or prevalence of oral cancer is known to be directly reported. Variability in age-adjusted incidence with crude incidence is projected to increase by 2030. Challenges focus on measurement of disease incidence and disease-specific risk behavior, predominantly, alcohol, and tobacco use. Future research should be aimed at improving quality of data for early detection and prevention of oral cancer.

Trends in the incidence and mortality of oral cancer in Nevada (Preprint)

2020 ◽  
Author(s):  
Kevin Foote ◽  
Karl Kingsley
Keyword(s):  
Public Health ◽  
Oral Cancer ◽  
Cancer Incidence ◽  
Cancer Control ◽  
Cancer Registries ◽  
Public Health Research ◽  
Chi Square ◽  
Incidence And Mortality ◽  
The Us ◽  
Chi Square Analysis

BACKGROUND Reviews of national and state-specific cancer registries have revealed differences in rates of oral cancer incidence and mortality that have implications for public health research and policy. Many significant associations between head and neck (oral) cancers and major risk factors, such as cigarette usage, may be influenced by public health policy such as smoking restrictions and bans – including the Nevada Clean Indoor Act of 2006 (and subsequent modification in 2011). OBJECTIVE Although evaluation of general and regional advances in public policy have been previously evaluated, no recent studies have focused specifically on the changes to the epidemiology of oral cancer incidence and mortality in Nevada. METHODS Cancer incidence and mortality rate data were obtained from the National Cancer Institute (NCI) Division of Cancer Control and Population Sciences (DCCPS) Surveillance, Epidemiology and End Results (SEER) program. Most recently available rate changes in cancer incidence and mortality for Nevada included the years 2012 – 2016 and are age-adjusted to the year 2000 standard US population. Comparisons of any differences between Nevada and the overall US population were evaluated using Chi square analysis. RESULTS This analysis revealed that the overall rates of incidence and mortality from oral cancer in Nevada differs from that observed in the overall US population. For example, although the incidence of oral cancer among Caucasians is increasing in Nevada and the US overall, it is increasing at nearly twice that rate in Nevada, P=0.0002. In addition, although oral cancer incidence among Minorities in the US is declining, it is increasing in Nevada , P=0.0001. Analysis of reported mortality causes revealed that mortality from oral cancer increased in the US overall but declined in Nevada during the same period (2012-2016). More specifically, mortality among both Males and Females in the US is increasing, but is declining in Nevada, P=0.0027. CONCLUSIONS Analysis of the epidemiologic data from Nevada compared with the overall US revealed significant differences in rates of oral cancer incidence and mortality. More specifically, oral cancer incidence increased in Nevada between 2012-2016 among all groups analyzed (Males, Females, White, Minority), while decreases were observed nationally among Females and Minorities. Although mortality in Nevada decreased over this same time period (in contrast to the national trends), the lag time between diagnosis (incidence) and mortality suggests that these trends will change in the near future. CLINICALTRIAL Not applicable

scholarly journals Mapping evidence on the distribution of paediatric cancers in sub-Saharan Africa: a scoping review protocol

2019 ◽  
Vol 8 (1) ◽  
Author(s):  
Sehlisiwe R. Ndlovu ◽  
Desmond Kuupiel ◽  
Themba G. Ginindza
Keyword(s):  
Scoping Review ◽  
Low Income ◽  
Relevant Literature ◽  
Sub Saharan Africa ◽  
World Health ◽  
Low Income Countries ◽  
Future Research ◽  
International Agency ◽  
Healthcare Needs ◽  
Sub Saharan

Abstract Background Paediatric cancers account for a minor fraction of deaths and hence receive little attention from policymakers. In low-income countries, the absence of comprehensive national paediatric strategies results in a lack of access for a majority of children with cancer. In sub-Saharan Africa (SSA), the burden of childhood cancers is underestimated due to a lack of paediatric cancer registries, poor health care systems and competing healthcare needs. The objective of this study is to map evidence on the distribution of paediatric cancers in the SSA region. Method A scoping review will be conducted to map literature on the distribution of paediatric cancers in SSA. An electronic literature search will be conducted from the following databases: PubMed, Google Scholar, EBSCOhost (CINAHL and Health Source) and World Health Organization (WHO)/International Agency for Research in Cancer (IARC) (GLOBOCAN databases). We will also search the reference lists of included studies to source relevant literature. A pilot search was conducted to determine the feasibility of the study. Study selection will be guided by the inclusion and exclusion criteria. After charting the data, a descriptive overview of the studies will be presented in a narrative format. An account of the study characteristics will be described in this narrative. The analysis will be mainly based on mapping the country-specific outcomes emerging from the studies, and a numerical summary of these outcomes will be conducted. Tables, maps and charts will be produced and presented in the result section. Discussion This review study will identify existing research gaps for future research to influence policy implementation and to improve the availability of diagnosis and treatment of paediatric cancers in SSA.

scholarly journals Global Consultation on Cancer Staging: To Promote Consistent Understanding and Use of Cancer Stage Terminology

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 151s-151s
Author(s):  
B. O'Sullivan ◽  
F. Moraes ◽  
S.H. Huang ◽  
M. Malcolm ◽  
J. Brierley ◽  
...  
Keyword(s):  
Cancer Control ◽  
Cancer Staging ◽  
Cancer Registries ◽  
The United States ◽  
Cancer Surveillance ◽  
International Agency ◽  
Cancer Stage ◽  
Disease Extent ◽  
Increased Risk ◽  
Staging Systems

Background and context: Although the TNM stage schema has been the traditional means to classify anatomic extent of disease, in recent years confusion and uncertainty have emerged which underpinned by lack of familiarity concerning underlying rules of staging and their application. In turn such lack of clarity has led increased risk of miscommunication regarding patient care, research, cancer surveillance, epidemiology and cancer control. The UICC TNM Committee has confirmed a lack of uniformity in the application of cancer stage and its rules. In addition to stage, numerous other factors influence the outcome of patients as relate to tumor characteristics, patient descriptors, and the environment where any treatment is administered. A particularly a frequent problem is mixing disease extent and biology which has promoted additional misunderstanding about the importance and relevance of different individual prognostic elements and to what degree biology vs disease burden contribute to outcome. Aim: To ensure uniformity of staging systems, rules and classifications, the TNM Committee developed a global consensus on cancer staging. Strategy/Tactics: A selected literature review of twelve high impact oncology journals was performed and results will be summarized. There was inconsistent understanding and use of cancer stage classification terminology evident in up to 20% of the literature. A survey was developed and found that only 12.5% of those surveyed thought that the application of the TNM staging terminology was consistent and uniform in the literature. Respondents believed that complete T, N and M data should be recorded in cancer registries, 71% considered that other predictive and prognostic factors should also be collected by central cancer registries but that anatomic disease extent should be collected as a separate variable (85%). The Global Consultation on Cancer Staging was held under the auspices of the Union for International Cancer Control (UICC) and Lancet Oncology with support from the United States (US) National Cancer Institute (NCI) and the US Centers for Disease Control and Prevention (CDC). Experts from these organizations and FIGO (Fédération Internationale de Gynécologie et d´Obstétrique), IACR (International Association of Cancer Registries), IARC (International Agency for Research in Cancer), and the ICCR (International Collaboration on Cancer Reporting) attended. Program/Policy process: The purpose of the staging classification was reaffirmed. Important issues about staging processes were annunciated, and inconsistencies in terminology and use were acknowledged. Definitions of frequently misused staging terms were clarified. What was learned: It was determined that methodologies need to be explored to identify and include necessary data elements relevant to personalized treatment. Selection of factors should particularly include attention to their inclusion in cancer registries where appropriate.

scholarly journals Anti-angiogenesis Therapy in Cancer Treatment

2019 ◽  
Vol 35 (1) ◽  
Author(s):  
Thi Thanh Binh Nguyen ◽  
Dang Thi Ngan ◽  
Nguyen Thanh Hai
Keyword(s):  
Growth Factor ◽  
Cancer Therapy ◽  
Targeted Delivery ◽  
Cancer Control ◽  
The United States ◽  
World Health ◽  
International Agency ◽  
Clinical Cancer Research ◽  
Health Organization ◽  
Endothelial Growth Factor

Angiogenesis plays a crucial role in the proliferation, invasion and metastasis of cancer cells. Unlike conventional chemotherapy, anti-angiogenesis drugs inhibit the formation of new blood vessels, reduce the nutrition and oxygen supply to the tumour, thus halting disease progression. In the last fifteen years, Food and Drug Administration of the United States has approved more than ten anti-cancer drugs of this group, namely the monoclonal antibody bevacizumab and small molecules drugs such as temsirolimus, sunitinib, axitinib and sorafenib. Other anti-angiogenesis agents are currently undergoing clinical trials. In addition to treating cancer, these agents have also potential applications in the treatment of complications related to angiogenesis in diabetes, arthritis, psoriasis and collagen-related diseases. Keywords Anti-angiogenesis, angiogenesis, cancer, metastasis, treatment. References [1] International Agency for Research on Cancer WHO, International agency for research on cancer – world health organization. https://www.iarc.fr/featured-news/latest-global-cancer-data-cancer-burden-rises-to-18-1-million-new-cases-and-9-6-million-cancer-deaths-in-2018 (accessed 19 February 2019).[2] International Agency for Research on Cancer France, Cancer today - International agency for research on cancer – world health organization. https://gco.iarc.fr(accessed 19 February 2019).[3] D.W. Siemann, M.C. Bibby, G.G. Dark, A.P. Dicker, FALM. Eskens, et al. Differentiation and Definition of Vascular-Targeted Therapies. Clinical Cancer Research. 11(2) (2005) 416–420.[4] J. Folkman, Tumor angiogenesis: therapeutic implications, The New England Journal of Medicine. 285(21) (1971) 1182-1186.[5] D. Hanahan, J. Folkman. Patterns of emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86(3) (1996) 353–64.[6] G. Gasparini. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs. 58(1) (1999) 17-38.[7] J. Folkman, E. Braunwald, A.S. Fauci, D.L. Kasper, S.L. Hauser, D.L. Longo, J.L. Jameson, editors. Angiogenesis. Harrison’s textbook of internal medicine. fifteen ed. McGraw-Hill, New York, 2001. pp. 517–530.[8] J. Folkman. Angiogenesis research: From Laboratory to clinic. Forum Genova. 9(3) (1999) 59–62.[9] S. Liekens, E. De Clercq, J. Neyts. Angiogenesis: Regulators and clinical applications. Biochemical Pharmacology. 61(3) (2001) 253–270.[10] L. Rosen. Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers, Cancer Control. 9(2) (2002) 36-44.[11] A.L. Harris. Angiogenesis as a new target for cancer control. European Journal of Cancer Supplements. 1(2) (2003) 1-12.[12] D.W. Siemann. Vascular Targeting Agents. horizons in cancer therapeutics from bench to bedside. 3(2) (2002) 4–15.[13] B.G. Wouters, S.A. Weppler, M. Koritzinsky, W. Landuyt, S. Nuyts, et al. Hypoxia as a target for combined modality treatments, European Journal of Cancer. 38(2) (2002) 240–257.[14] P. Carmeliet, R.K. Jain. Angiogenesis in cancer and other diseases. Nature. 407(6801) (2000) 249-257.[15] J.W. Rak, B.D. St. Croix, R.S. Kerbel. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs. 6(1) (1995) 3–18.[16] J. Hamada, P.G. Cavanaugh, O. Lotan, G.L. Nicolson. Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. British Journal of Cancer. 66(2) (1992) 349-54.[17] J. Denekamp. Vascular attack as a therapeutic strategy for cancer. Cancer and Metastasis Reviews. 9(3) (1990) 267–282.[18] J. Denekamp. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. The British Institute of Radiology. 66(783) (1993) 181–186.[19] H.P. Eikesdal, H. Sugimoto, G. Birrane, Y. Maeshima, V.G. Cooke, et al. Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. Proceedings of the National Academy of Sciences of the United States of America. 105(39) (2008) 15040–15045.[20] F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Fontanini, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa),a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clinical Cancer Research. 7(5) (2001) 1459–1465.[21] T. Kamba, D.M. McDonald. Mechanisms of adverse effects of anti-VEGF therapy for cancer. British Journal of Cancer. 96(12) (2007) 1788–1795.[22] S.M. Gressett, S.R. Shah. Intricacies of bevacizumab-induced toxicities and their management. Annals of Pharmacotherapy. 43(3) (2009) 490–501[23] S. Goel, D.G. Duda, L. Xu, L.L. Munn, Y. Boucher, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiological Reviews. 91(3) (2011) 1071–1121.[24] T. Sudha, D.J. Bharali, M. Yalcin, N.H. Darwish, M.D. Coskun, et al. Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac. International Journal of Nanomedicine. 12(3) (2017) 1305–1315.[25] T. Sudha, D.J. Bharali, M. Yalcin, N.H. Darwish, M.D. Coskun, et al. Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac. Nanomedicine. 12(3) (2017) 195–205.[26] M.Rajabi, S.A. Mousa. The Role of Angiogenesis in Cancer Treatment. Biomedicines. 5(2) (2017) 34-45.[27] J.Y. Hsu, H.A. Wakelee. Monoclonal antibodies targeting vascular endothelial growth factor: Current status and future challenges in cancer therapy. BioDrugs. 23(5) (2009) 289–304.[28] M. Zhou, P. Yu, X. Qu, Y. Liu, J. Zhang. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: A meta-analysis, Plos One. 8(12) (2013) e81858.[29] D.H. Johnson, L. Fehrenbacher, W.F. Novotny, R.S. Herbst, J.J. Nemunaitis, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology. 22(11) (2004) 2184–2191.[30] B.J. Giantonio, D.E. Levy, P.J. O’Dwyer, N.J. Meropol, P.J. Catalano, et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group study E2200, Annals of Oncology. 17(9) (2006) 1399–1403.

Cancer registries in oral cancer control in India

2015 ◽  
Vol 4 ◽  
pp. 13-14
Author(s):  
Priya Mohan ◽  
Harry A. Lando
Keyword(s):  
Oral Cancer ◽  
Cancer Control ◽  
Cancer Registries

scholarly journals 1375Age-standardization to world population and under-estimation of oral cancer burden

2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Kishore Chaudhry ◽  
Prashanti Bollu
Keyword(s):  
Oral Cancer ◽  
Incidence Rate ◽  
Cancer Incidence ◽  
Cancer Registries ◽  
Healthcare Services ◽  
Incidence Rates ◽  
International Agency ◽  
World Population ◽  
Crude Incidence Rate ◽  
Crude Incidence

Abstract Background Age-standardization is common for adjustment of unequal population in different ages as it can influence cancer incidence. However, for planning healthcare services (including screening), one needs absolute magnitude since everyone needs intervention. This study assessed the effect of age-standardization on understanding the global differentials in magnitude of oral cancer. Methods Data on cancer incidence rates of oral cancers for 2008-2012, was obtained from the website of international agency for research on cancer for all 334 population-based cancer registries. Scatter plots were prepared between age-standardized and crude incidence rates to assess the ratio between them according to proportion of old people for all countries. Areas with high occurrence of oral cancer were identified. Results The ratio between age-standardized and crude incidence rate was >1 in countries with high proportion of older population (high-development-index countries), indicating an artificial widening of gap between incidence rates between countries due to age-standardization. Six areas had higher crude incidence rate among men than India. Based on the published estimates, the per-unit-population burden in Europe was 6.3% higher than India, while in USA it was merely 12.5% lower than India. Conclusions The perception of low burden of oral cancer in high-economy countries is artificial, brought about by common practice of age-standardization. Key messages Organization of oral cancer screening activities by countries with resources and expertise will provide much needed knowledge on its natural history and efficacy of control strategies.

scholarly journals What are cancer registries

2004 ◽  
Vol 57 (1-2) ◽  
pp. 27-29
Author(s):  
Marica Miladinov-Mikov
Keyword(s):  
Cancer Registry ◽  
Geographical Area ◽  
Cancer Control ◽  
Cancer Registries ◽  
Population Based ◽  
International Agency ◽  
World Population ◽  
The World ◽  
The Individual ◽  
The Impact

Introduction Population-based cancer registries attempt to collect, process, analyze, store and interpret data on persons with cancer in a certain population (most frequently a geographical area). Hospital-based cancer registries register all cases in a given hospital, usually without knowledge of the background population; the emphasis is to serve the needs of the hospital administration, the hospital cancer program, and, above all, the individual patient. History of Cancer Registries Registration of persons suffering from cancer is a slow process. Around the year 1900, England and Germany demanded improvement of statistical investigation on spread of cancer in population in order to undertake etiological researches. The oldest example of a modern cancer registry is that in Hamburg. Today there are more than 200 population-based cancer registries, but they cover only 5% of the world population, mainly in developed countries of the world. Cancer registry of Vojvodina Cancer registry of Vojvodina was established in 1966; it is a member of International Agency for Research on Cancer (IARC) and it is still the only cancer registry from our country whose data are cited in scientific monographs of IARC. The main purpose of cancer registries is to produce statistics on the occurrence of cancer in a defined populatin and to provide a framework for assessing and controlling the impact of cancer on the community. Cancer registries are essential parts of any rational program of cancer control. Their data can be used in a wide variety of areas of cancer control, ranging from etiological research in epidemiology, through primary and secondary prevention to health-care planning and patient care, so benefiting both the individual and society.

scholarly journals Novel coronavirus associated with severe respiratory disease: Case definition and public health measures

2012 ◽  
Vol 17 (39) ◽  
Author(s):  
N Danielsson ◽  
collective on behalf of the ECDC Internal Response Team ◽  
M Catchpole
Keyword(s):  
Public Health ◽  
Case Definition ◽  
World Health ◽  
Public Health Response ◽  
Health Measures ◽  
Health Response ◽  
Disease Case ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

Two cases of rapidly progressive acute respiratory infection in adults associated with a novel coronavirus have generated an international public health response. The two infections were acquired three months apart, probably in Saudi Arabia and Qatar. An interim case definition has been elaborated and was published on the World Health Organization website on 25 September 2012.

scholarly journals 120. A Randomized Double-blind Trial Assessing the Efficacy of M72/AS01E Vaccine Against Pulmonary Tuberculosis Disease in Adults With Latent Mycobacterium tuberculosis Infection

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S5-S6
Author(s):  
Olivier Van Der Meeren ◽  
Mark Hatherill ◽  
Videlis Nduba ◽  
Robert J Wilkinson ◽  
Monde Muyoyeta ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Disease Incidence ◽  
Case Definition ◽  
Eastern Africa ◽  
Case Definitions ◽  
Double Blind ◽  
Pulmonary Tb ◽  
Disease Case ◽  
Grant Recipient ◽  
Research Grant

Abstract Background An effective tuberculosis (TB) vaccine is urgently needed to support the End TB Strategy to reduce the number of new TB cases by 80% by 2030. M72/AS01E candidate vaccine is an adjuvanted recombinant fusion protein derived from Mycobacterium tuberculosis Mtb32A and Mtb39A proteins. Methods We conducted a randomized, double-blind, placebo-controlled phase 2b trial (NCT01755598) in Southern and Eastern Africa to assess M72/AS01E’s efficacy against bacteriologically confirmed pulmonary TB disease in HIV-seronegative (HIV–) adults aged 18–50 years infected with Mtb (defined by a positive IFN-γ release assay). Participants were randomized 1:1 to receive M72/AS01E or placebo at day D0 and D30. Reactogenicity, safety, immunogenicity were assessed, and incident TB disease measured from D30 postdose 2 up to ≥24 months for this analysis (follow-up ongoing up to 37 months). Efficacy against various TB disease case definitions (Figure 1) was estimated. Primary objective: efficacy against culture- or PCR-confirmed pulmonary TB disease in HIV– adults (case definition 1; success criterion: lower limit of 90% 2-sided CI >0%, power: 80%). Results Demographic characteristics were similar between M72/AS01E (1786) and placebo (1787) recipients. Efficacy against pulmonary TB disease case definition 1 was 54.0% (90% CI: 13.9, 75.4; P = 0.042); efficacy against other case definitions and a sensitivity analysis are shown in Figure 1. Leading solicited symptoms were pain, fatigue, and headache (Figure 2). In all recipients, unsolicited symptoms (D0–29) were more frequent after M72/AS01E (67.4%) than placebo (45.4%), mainly attributable to increased injection site reactions and flu-like symptoms. Serious adverse events (D0–month 7) incidences were similar between groups (M72/AS01E: 1.6%; placebo: 1.8%). During the study, 24 adults died (14 due to traumatic events); all deaths were unrelated to the trial. Conclusion M72/AS01E presents a clinically acceptable safety profile and significantly reduces bacteriologically confirmed pulmonary TB disease incidence in HIV– adults with latent Mtb infection. Funding. BMGF; Aeras; DFID UK; DGIS; AusAID; GlaxoSmithKline Biologicals SA. Disclosures O. Van Der Meeren, GSK: Employee and Shareholder, Salary. M. Hatherill, Aeras: Investigator, Research grant. R. J. Wilkinson, GSK: Grant Investigator, indirect funding. H. M. Ayles, GSK: Grant Investigator, Research grant. G. Henostroza, Aeras: Investigator, Grant recipient. M. A. Demoitié, GSK: owns stocks and is named inventor on patent applications relating to certain uses of M72/AS01E, Salary. T. Singh, GSK: Employee and Shareholder, Salary. E. J. Akite, GSK: Employee, Salary. A. K. Azam, GSK: Employee, Salary. A. Bollaerts, GSK: Employee, Salary. A. M. Ginsberg, GSK: Collaborator, Research support. BMGF: Grant Investigator, Grant recipient. UK DFID: Grant Investigator, Grant recipient. P. Gillard, GSK: Employee and Shareholder, Salary and stock. D. R. Tait, Aeras: Employee, Salary. GSK: Shareholder, Salary.

scholarly journals SUN-302 Incidence Trends in Lung and Gastroenteropancreatic Neuroendocrine Neoplasms

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Heba Alwan ◽  
Stefano La Rosa ◽  
Peter Kopp ◽  
Simon Germann ◽  
Manuela Maspoli-Conconi ◽  
...  
Keyword(s):  
Cancer Registries ◽  
Population Based ◽  
Incidence Rates ◽  
World Health ◽  
International Agency ◽  
Neuroendocrine Neoplasms ◽  
Incidence Trends ◽  
Time Period ◽  
Well Differentiated ◽  
Health Organization

Abstract Abstract Introduction The incidence of neuroendocrine neoplasms (NENs) seems to increase worldwide. However, long-term, population-based data that consider differentiation levels are sparse. Objective To evaluate the incidence trend of lung and gastroenteropancreatic (GEP) NENs according to the latest International Agency for Research on Cancer/World Health Organization classification over a 41-year time period in two Swiss regions. Methods All cases of lung and GEP NENs recorded in the Vaud and Neuchâtel Cancer Registries from 1976–2016 were included. NENs were stratified into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Changes in annual age-standardized incidence rates were calculated for lung and GEP NETs and NECs by sex. Results There were 4141 patients diagnosed with NENs, of which 65% were men. The incidence of lung NETs did not reveal any statistically significant trend in men, but increased in women by 4.9%/year between 1976–2016. The incidence of lung NECs in men decreased significantly by 2.6%/year from 1985–2016 whereas the incidence of lung NECs in women increased significantly between 1976–1998 by 6%/year. For GEP NETs, a steady annual increase in incidence occurred between 1976–2016 with a magnitude of 1.7% in men and 1.3% in women. No trend in incidence of GEP NECs was found for both sexes. Conclusions The incidence trends of lung NECs in men and women parallel changes in smoking prevalence in the population whereas causes of the increase in incidence of GEP NETs are not fully understood. Our study supports the importance of evaluating the epidemiology of NENs by their differentiation level.

Sign in / Sign up

Export Citation Format

Share Document